PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the addition of Ellen B.…
Cognitive Therapeutics goes public, Explorer Surgical acquired
MINNEAPOLIS (Oct. 25, 2021) – Sofia Fund, the angel investment firm focused exclusively on women-led companies, announces new milestones: two of its portfolio companies have progressed onto their next stages of growth, providing returns for Sofia’s group of investors.…
Women-led biopharmaceutical company Cognition Therapeutics newly public stock started trading Oct. 8. CGTX (new NASDAQ ticker) innovates therapeutics that target age-related degenerative diseases and disorders. See the news here: https://ir.cogrx.com/news-releases/news-release-details/cognition-therapeutics-announces-pricing-upsized-initial-public…
Sofia Fund portfolio company Oculogica signs on one of the largest neurology clinics in the U.S. to use its device.
This is a major innovation as CTE (chronic traumatic encephalopathy) is currently only diagnosed after death.
In partnership with Dr. Sarah de la Torre, Ob-Gyn and functional medicine expert, Joylux has designed science-based products, digital tools, and relevant information to help women thrive during this phase of their life.
Oculogica’s patent enables expansion of its eye-tracking based technology to fulfill an unmet need in cannabis impairment detection
Kenzen’s predictive body heat sensor system for industrial workers has been named a Product of the Year by Occupational Health & Safety magazine.
Read full article here or download a copy here (2.9MB PDF).…
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660.
This is a major milestone in Rebiotix’s efforts to bring the first microbiota-based therapeutic to the market to treat people that have recurrent Clostridioides difficile infection (rCDI).…
Sofia Fund participates in recently closed $8M financing round announced by existing portfolio company, Oculogica. This round of funding will support further commercial distribution of the EyeBOX at Level I, II and III trauma centers nationwide, including additional units in use with the U.S.…